The Company has a 401(k) plan that provides a retirement benefit to substantially all full-time U.S. employees. Eligible employees may contribute a percentage of their annual compensation, subject to Internal Revenue Service limitations, with the Company matching a portion of the employees’ contributions at the discretion of the Company. Matching contributions totaled $128,000 and $88,000 for the years ended December 31, 2025, and 2024, respectively.

On August 7, 2025, the Company announced its decision to exit substantially all of its international operations in order to focus exclusively on the U.S. market—where the Company is seeing the strongest growth and clinical demand. With expanding traction in U.S. cardiac surgery and pediatric programs, and a rising opportunity in the hospital-based outpatient space, the Company is streamlining to prioritize investment in markets where it can have the most immediate and long-term impact. As of December 31, 2025, the Company has accrued approximately $246,000 in contractual exit fees and product repurchase obligations with certain of its former international distributors. This amount is included in “Accounts payable and accrued liabilities” line on the Consolidated Balance Sheet. These accrued contractual exit fees and product repurchase obligations will be substantially paid out by the end of the first quarter of fiscal 2026.

On September 11, 2025, the Company entered into a research and development collaboration agreement with Koronis Biomedical Corporation (KBT) to design and develop certain technology having utility in renal replacement therapy for small children and neonates with acute kidney injury, fluid overload and kidney failure. This agreement became effective on September 5, 2025, when KBT received approval of a $3.0 million grant from the National Institutes of Health (NIH) to support this project. As part of this agreement, the Company will pay KBT a non-refundable technology license fee of $600,000, payable in eighteen monthly installments commencing on January 1, 2027. The Company can unilaterally terminate the Agreement at any time for any reason making future installments avoidable. No unconditional obligation exists until each installment becomes due. Installments are expensed as Research and Development only when due. Discounting is not applied because the installments do not represent a present obligation.

Commitments and Contingencies	12 Months Ended
Dec. 31, 2025
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 9—Commitments and Contingencies Employee Retirement Plan The Company has a 401(k) plan that provides a retirement benefit to substantially all full-time U.S. employees. Eligible employees may contribute a percentage of their annual compensation, subject to Internal Revenue Service limitations, with the Company matching a portion of the employees’ contributions at the discretion of the Company. Matching contributions totaled $128,000 and $88,000 for the years ended December 31, 2025, and 2024, respectively. International Exit On August 7, 2025, the Company announced its decision to exit substantially all of its international operations in order to focus exclusively on the U.S. market—where the Company is seeing the strongest growth and clinical demand. With expanding traction in U.S. cardiac surgery and pediatric programs, and a rising opportunity in the hospital-based outpatient space, the Company is streamlining to prioritize investment in markets where it can have the most immediate and long-term impact. As of December 31, 2025, the Company has accrued approximately $246,000 in contractual exit fees and product repurchase obligations with certain of its former international distributors. This amount is included in “Accounts payable and accrued liabilities” line on the Consolidated Balance Sheet. These accrued contractual exit fees and product repurchase obligations will be substantially paid out by the end of the first quarter of fiscal 2026. Technology License Fee On September 11, 2025, the Company entered into a research and development collaboration agreement with Koronis Biomedical Corporation (KBT) to design and develop certain technology having utility in renal replacement therapy for small children and neonates with acute kidney injury, fluid overload and kidney failure. This agreement became effective on September 5, 2025, when KBT received approval of a $3.0 million grant from the National Institutes of Health (NIH) to support this project. As part of this agreement, the Company will pay KBT a non-refundable technology license fee of $600,000, payable in eighteen monthly installments commencing on January 1, 2027. The Company can unilaterally terminate the Agreement at any time for any reason making future installments avoidable. No unconditional obligation exists until each installment becomes due. Installments are expensed as Research and Development only when due. Discounting is not applied because the installments do not represent a present obligation.